The efficiency of bazedoxifene, another endocrine therapy agent (estrogen-receptor agonist/antagonist), was evaluated in endocrine-resistant HR+ breast cancer patients during clinical trial NCT02448771 (Table 3). This evidence concerns the gene ESR1 and breast carcinoma.